Dean Felsher
Dean Felsher
Professor of Medicine-Oncology, Pathology, Stanford University
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
MYC regulates the antitumor immune response through CD47 and PD-L1
SC Casey, L Tong, Y Li, R Do, S Walz, KN Fitzgerald, AM Gouw, V Baylot, ...
Science 352 (6282), 227-231, 2016
Reversible tumorigenesis by MYC in hematopoietic lineages
DW Felsher, JM Bishop
Molecular cell 4 (2), 199-207, 1999
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma
AP Weng, JM Millholland, Y Yashiro-Ohtani, ML Arcangeli, A Lau, C Wai, ...
Genes & development 20 (15), 2096-2109, 2006
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
CM Shachaf, AM Kopelman, C Arvanitis, Å Karlsson, S Beer, S Mandl, ...
Nature 431 (7012), 1112-1117, 2004
MYC as a regulator of ribosome biogenesis and protein synthesis
J Van Riggelen, A Yetil, DW Felsher
Nature Reviews Cancer 10 (4), 301-309, 2010
MYC activation is a hallmark of cancer initiation and maintenance
M Gabay, Y Li, DW Felsher
Cold Spring Harbor perspectives in medicine 4 (6), a014241, 2014
Sustained loss of a neoplastic phenotype by brief inactivation of MYC
M Jain, C Arvanitis, K Chu, W Dewey, E Leonhardt, M Trinh, CD Sundberg, ...
Science 297 (5578), 102-104, 2002
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
C Ma, AH Kesarwala, T Eggert, J Medina-Echeverz, DE Kleiner, P Jin, ...
Nature 531 (7593), 253-257, 2016
Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy
Z Liu, AC Fan, K Rakhra, S Sherlock, A Goodwin, X Chen, Q Yang, ...
Angewandte Chemie International Edition 48 (41), 7668-7672, 2009
HIF-dependent antitumorigenic effect of antioxidants in vivo
P Gao, H Zhang, R Dinavahi, F Li, Y Xiang, V Raman, ZM Bhujwalla, ...
Cancer cell 12 (3), 230-238, 2007
Transient excess of MYC activity can elicit genomic instability and tumorigenesis
DW Felsher, JM Bishop
Proceedings of the National Academy of Sciences 96 (7), 3940-3944, 1999
Cancer revoked: oncogenes as therapeutic targets
DW Felsher
Nature Reviews Cancer 3 (5), 375-379, 2003
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation
CH Wu, J Van Riggelen, A Yetil, AC Fan, P Bachireddy, DW Felsher
Proceedings of the National Academy of Sciences 104 (32), 13028-13033, 2007
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis
Y Xiang, ZE Stine, J Xia, Y Lu, RS O’Connor, BJ Altman, AL Hsieh, ...
The Journal of clinical investigation 125 (6), 2293-2306, 2015
Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo
D Ye, AJ Shuhendler, L Cui, L Tong, SS Tee, G Tikhomirov, DW Felsher, ...
Nature chemistry 6 (6), 519-526, 2014
CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation
K Rakhra, P Bachireddy, T Zabuawala, R Zeiser, L Xu, A Kopelman, ...
Cancer cell 18 (5), 485-498, 2010
Cancer prevention and therapy through the modulation of the tumor microenvironment
SC Casey, A Amedei, K Aquilano, AS Azmi, F Benencia, D Bhakta, ...
Seminars in cancer biology 35, S199-S223, 2015
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
R Dhanasekaran, A Deutzmann, WD Mahauad-Fernandez, AS Hansen, ...
Nature reviews Clinical oncology 19 (1), 23-36, 2022
c-Myc is a critical target for c/EBPα in granulopoiesis
LM Johansen, A Iwama, TA Lodie, K Sasaki, DW Felsher, TR Golub, ...
Molecular and cellular biology 21 (11), 3789-3806, 2001
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead
WH Goodson III, L Lowe, DO Carpenter, M Gilbertson, A Manaf Ali, ...
Carcinogenesis 36 (Suppl_1), S254-S296, 2015
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20